Internalization and degradation of filamentous bacteriophage M13 by a specific target cell may have major consequences for the recovery of phage in in vivo biopanning of phage libraries. Therefore, we investigated the pharmacokinetics and processing of native and receptor-targeted phage in mice.
INTRODUCTION
The development of phage display technology has considerably facilitated the design of specific peptide ligands or antibody fragments that bind to receptors and target proteins, the majority of selections being performed in vitro against immobilized antigens or cells (Scott and Smith, 1990 ). In addition, in vivo biopanning proved to be successful in the identification of organspecific ligands (Pasqualini and Ruoslahti, 1996) . Illustratively, in vivo phage display has been used to isolate peptides which target tumor blood vessels and which could be used to enhance the efficacy of the anticancer drug doxorubicin against human breast cancer xenografts in mice . Other groups have exploited in vivo biopanning to identify homing devices for atherosclerosis in low density Lipoprotein-receptor (LDLr) knockout mice (Houston et al., 2001) , tracheal tumors (Kennel et al., 2000) , thymic endothelium (Johns et al., 2000) , and several other organs (Rajotte et al., 1998) . In these studies, however, the fate of phage in vivo has not been quantitatively assessed, and selection was only restricted to endothelial targets. We hypothesized that internalization and degradation of phage after receptor binding may significantly affect its recovery in vivo. The ability of phage to be internalized was first shown for phage displaying the Arg-Gly-ASP (RGD) motif (Hart et al., 1994) . This observation was exploited to enhance the stringency of selection in phage display protocols and to screen for ligands that confer efficient uptake by a specific cell type (Barry et al., 1996; Ivanenkov et al., 1999a; Becerril et al., 1999) . Internalizing phage were selected against tumors (Poul et al., 2000) , Epidermal Growth Factor (EGF) receptor (Heitner et al., 2001) , and even phage with transcytotic capacity have been recovered (Ivanenkov and Menon, 2000) . Interestingly, Larocca et al. have used internalizing phage to establish GFP and ␤-Gal expression in mammalian cells (Larocca et al., , 1998 Kassner et al., 1999) . Recently, Giovine et al. showed DNA transfection of phage via integrins (Giovine et al., 2001) . After uptake, the internalized phage enter endosomal compartments (Ivanenkov et al., 1999b) . Their recovery could be significantly improved by the lysosomotropic agent chloroquine, suggesting that internalized phage are indeed efficiently degraded upon uptake. The processing and potential degradation of phage after receptor-mediated internalization by a specific receptor may have major consequences for the recovery of phage in selection protocols in vivo. Therefore, it is essential to have detailed information on the in vivo fate of native phage and of specific phages with high affinity for a well-established internalizing receptor, measuring total amount of tissue-associated phage particles rather than colony forming units (infectious phage).
In the present study, M13 were metabolically labeled with [
35 S]methionine/cysteine to quantitatively assess the pharmacokinetics of native and targeted phage particles. As a model of a selected, receptor-specific phage clone, phage were chemically modified by reductive lactosamination (lacM13) or succinylation (sucM13) to stimulate uptake by hepatic galactose receptors or by scavenger receptors on endothelial cells and macrophages, respectively. We show that 35 S-radiolabeled phage-targeting galactose or scavenger receptors are more rapidly and specifically taken up in vivo by the liver than nonmodified phage, making these chemical modifications not only representative tools for in vivo kinetic studies, but also interesting for the use of bacteriophage M13 as a gene delivery vehicle. Moreover, we demonstrate that internalized phage are rapidly inactivated after tissue uptake and provide evidence for possible extravasation of the phage into subendothelial tissue, which has implications for the phage display selection protocols in vivo.
RESULTS

Serum decay and tissue distribution of bacteriophage M13
First, the tissue distribution and serum clearance of unmodified M13 were investigated. C57Bl/6KH were injected with 35 S-labeled M13 and the plasma recovery of 35 S-radioactivity and colony forming units (CFU) was determined at the indicated time points (Fig. 1A) . After 30 min, mice were perfused with DMEM through the right ventricle of the heart to remove nonbound phage. The biodistribution (Fig. 1B) and specific biodistribution (per gram tissue, Fig. 1C ) of 35 S-radioactivity and CFU were determined in the indicated organs as a percentage of the injected dose (%ID). Total recoveries of the organs and plasma as indicated in Fig. 1B were 98 and 102% for 35 S-radioactivity and CFU, respectively. The recovery of CFU in plasma, heart, and kidney correlated well with that of radioactivity. However, the recovery of CFU in liver, spleen, and lungs was found to be consistently lower than that of radioactivity in the same organ. As this was not the case for kidney and heart, and as CFU recovery in all organs were essentially 100% at 5 min postinjection (data not shown), it is unlikely that the low recovery of CFUs is owing to a loss of CFUs during the isolation procedure. Rather, the difference between CFUs and 35 S-radioactivity for liver, lungs, and spleen at 30 min after injection may be caused by lysosomal degradation of the phages after uptake by the target tissue. Comparable results were obtained for 129/ICR white mice. In these mice, the half-life of naked M13 was approximately 4 h. Uptake of 35 S-M13 was largest in liver (4.7% of ID) and spleen (0.8% of ID). Recovery of CFUs as compared to radiolabeled M13 was 50-80% lower for lungs, liver, and spleen, but identical for heart and kidney (not shown). This shows that the results obtained are not specific to one inbred strain of mice.
Serum decay and tissue distribution of succinylated and lactosylated M13
The above results show that bacteriophage M13 is cleared very slowly from the circulation. As a measure of a selected phage with affinity for a specific internalizing receptor, 35 S-M13 was chemically modified with lactose or succinic anhydride to induce receptor-mediated uptake by the hepatic galactose receptors and scavenger receptors, respectively. To exclude that the chemical modifications led to aggregation or disintegration of the bacteriophage, 35 S-lacM13 and 35 S-sucM13 were subjected to size exclusion (SE) chromatography on a Sephacryl S1000 column and the eluted fractions were assayed for radioactivity ( Fig. 2A) and CFUs (Fig. 2B) . The elution profiles of lacM13 and sucM13 correlated well with that of control M13, giving a broad peak at V elution ϭ 1.3 ml. Recoveries were Ͼ95%. Furthermore, the phage remained fully infective after the lactosylation and succinylation procedure, indicating that the chemical modifications did not affect the integrity of the virus.
To show the effect of the galactose and succinyl group on the in vivo behavior of the phage, mice were injected with 35 S-labeled sucM13 or lacM13 and both plasma clearance and biodistribution profile were determined. Figure 3A shows that the modifications led to an increased plasma clearance. The plasma half-life of M13 (4.5 h) was reduced to 18 and 1.5 min for lacM13 and sucM13, respectively. The rapid plasma clearance of sucM13 and lacM13 phage was accompanied by a changed biodistribution profile (Figs. 3B and 3C ). The major uptake site of sucM13 at 30 min after injection (determined as a percentage of the injected dose, Fig.  3B ), appeared to be liver (72 Ϯ 7%) and spleen (5.7 Ϯ 0.9%), whereas lacM13 was taken up mainly by the liver (50 Ϯ 1%). Uptake in the other organs was essentially similar to that of unmodified M13. Figure 3C shows the relatively large contribution of the spleen to the uptake of sucM13 (82 Ϯ 5% per gram tissue) but not for lacM13 (7.5 Ϯ 0.2%). Furthermore, a difference in recovery between the CFUs and 35 S-radioactivity was observed in the target organs at 30 min after injection. The recovery of CFUs as compared to 35 S-radioactivity (%ID) were only 26.6% (liver) and 42.6% (spleen) for sucM13 and 54.7% (liver) for lacM13 (not shown), suggesting that degradation of phage occurs as rapid as 30 min after injection. The results shown in Fig. 3 have also been conducted in 129/ICR white mice with essentially similar results, indi- cating that the effects observed are not related to one inbred strain of mice.
Uptake of lacM13 by liver cells
As demonstrated in the previous section, lacM13 is taken up solely by the liver. Hepatic uptake of lactosylated particles can be mediated by the asialoglycoprotein receptor (ASGPr) on parenchymal cells and the galactose particle receptor (GPr) on Kupffer cells. As the GPr predominantly recognizes larger galactose-exposing particles (Ͼ15 nm) (Bijsterbosch and Van Berkel, 1990; Biessen et al., 1996) , it is expected that the rod-like lactosylated M13 (6 ϫ 500 nm) is mainly targeted to the Kupffer cells. Moreover, parenchymal cells are subendothelial liver cells, shielded by endothelium-containing feneastrae of approximately 100 nm (Wisse et al., 1985) and thus supposedly inaccessible from the bloodstream for M13 phage. To confirm this, we determined the relative contribution of parenchymal liver cells (PC) and nonparenchymal cells (endothelial and Kupffer cells, NPC) to the hepatic uptake of lacM13. Mice were injected with 35 S-lacM13; after 20 min, the liver was perfused, and the PCs and NPCs were isolated (Ͼ95% purity, contamination of NPC in PC fraction Ͻ 1%) and assayed for CFU and 35 S-radioactivity (Fig. 4) . Indeed, the hepatic uptake of lacM13 could be mainly attributed to NPCs (92 Ϯ 4% of the total liver uptake of 35 S). However, despite the low accessibility of the PCs, still 8 Ϯ 3% of the injected dose could be recovered from the PCs. CFU values of the in vivo PC uptake (as a percentage of total CFU recovered) correlated well with 35 S-radioactivity, excluding that mainly phage degradation products were recovered from PCs. To check whether PCs are capable of taking up lacM13, binding and internalization of lacM13 was studied in vitro on isolated parenchymal cells by incubating the cells with lacM13 for 2 h at 37°C. Extracellular phage were removed by proteinase K and the remaining CFUs were determined (Fig. 5 ). Binding and uptake of lactosylated phage at 37°C occurred in a Ca 2ϩ -dependent fashion (not shown). Uptake of nonlactosylated library phage at 37°C and of lacM13 at 4°C was ϳ1000 times reduced ( Fig. 5) , establishing the essential role of galactose in the recognition of the PC. These data suggest that lacM13 is capable of passing the fenestrae and is specifically internalized by the ASGPr, albeit at a low efficacy. Inactivation of CFUs was also seen in vitro when lacM13 was recovered at different time points. The amount of lacM13 recovered after 6 h of incubation with isolated PCs was only 5% as compared to the amount recovered after 1 h. In the presence of chloroquine (an inhibitor of lysosomal degradation) recovery was 25%, showing that degradation was also present in isolated PCs and that degradation could be decreased by a factor of 5 in the presence of chloroquine.
Uptake and degradation of sucM13
It was shown above that succinylated M13 was rapidly cleared from the circulation (t 1/ 2 ϭ 1.5 min) and that the major uptake sites of sucM13 at 30 min after injection were liver (72 Ϯ 7%) and spleen (5.7 Ϯ 0.9%) (Figs. 3A and 3B). Succinylated HSA is solely taken up by scavenger receptors, mainly Scavenger Receptor A (SR-A), on liver and spleen macrophages and endothelial cells (Jansen et al., 1993a) . To confirm receptor specificity of sucM13, succinylated human serum albumin (sucHSA) was injected at a dose of 40 mg/kg 1 min prior to the injection of sucM13. SucHSA reduced the uptake of FIG. 5 . Uptake of lactosylated M13 by isolated mouse parenchymal cells. Freshly isolated mouse parenchymal cells (1.10 6 ) were incubated for 2 h at 37°C in 500 l DMEM/2%BSA in the presence of lactosylated M13 (lacM13, 37°C) or native M13 (M13, 37°C) at a concentration of 10 7 CFU/l. LacM13 was also incubated at 4°C (lacM13, 4°C) to inhibit ATP-driven uptake. Following incubation, cells were washed thoroughly and incubated with proteinase K (2 mg/ml) for 1 h at 4°C to remove membrane-bound phage. Proteinase K was quenched by PMSF (1 M) and after a subsequent wash, the cells were lysed by freeze thawing and the M13 content was determined through a colony assay (CFU). Binding and uptake are expressed as percentage of the input CFU and values represent means Ϯ variation of at least two experiments. sucM13 by liver and spleen to that of unmodified M13 (6% ID and 0.8% ID, respectively, data not shown), indicating that hepatic and splenic uptake can be completely prevented by blocking scavenger receptor-mediated uptake and that nonspecific association of sucM13 to liver and spleen is very low. To investigate the internalization rate of sucM13 in vivo, sucHSA was injected at 4 and 19 min after injection of sucM13 and the plasma radioactivity was determined (Fig. 6) . The amount of releasable (and thus membrane-associated) sucM13, calculated by correcting for control sucM13 serum levels, was 17% at 4 min after injection of 35 S-sucM13, while at 19 min only 6% of the tissue-associated radioactivity could be released. This indicates that within 20 min virtually all of the tissueassociated 35 S-sucM13 was inaccessible to sucHSA and probably internalized.
The low recovery of CFUs as compared to 35 S-radioactivity at 30 min after injection of unmodified M13 and modified M13 in mice pointed to phage degradation after uptake by the target tissue. The kinetics of degradation of 35 S-sucM13 after internalization were studied by comparing the recovery of phage-derived 35 S-radioactivity at the major elimination sites with that of infectious phage (CFU) at 10, 30, 90, and 360 min after injection. During this time span, the 35 S-radioactivity remained constant in all organs. The amount of CFUs, however, decreased dramatically after a 10 min (liver, spleen, lungs) or Ͼ30 min (kidney, heart) lag phase. As a measure of phage degradation in vivo, the recovery of infectious phage in the various organs, calculated as a percentage of the recovered radioactivity, is shown in Fig. 7 . The method of injection in Fig. 7 (tail vein injection instead of vena cava injection) did not influence the outcome of the results. Degradation was observed in all organs, but appeared to be most pronounced in the liver. In fact, phage infectivity in liver was reduced by a factor of 5000 within 90 min after injection, 100-fold more active than the degradation rate in the other organs.
DISCUSSION
So far, in vivo biopanning has been successfully applied for identifying peptides or antibodies targeting the vascular endothelium of specific organs (Pasqualini and Ruoslahti, 1996; Rajotte et al., 1998) , atherosclerotic lesions (Houston et al., 2001) , tracheal tumors (Kennel et al., 2000) , and thymic endothelium (Johns et al., 2000) . However, a quantitative biodistribution profile of (selected) phage has never been assessed, mainly because kinetic analysis was based on phage infectivity rather than on the number of phage particles (Yip et al., 1999) . As internalization and degradation of selected phage after receptor binding (Hart et al., 1994; Ivanenkov et al., 1999b) might perturb the outcome and interpretation of in vivo selections, the biodistribution profile of in vitro selected phage (Koivunen et al., 1999) , and the use of phage as a gene delivery vehicle Giovine et al., 2001; Monaci et al., 2001) , we have addressed the uptake and processing of wild-type and receptor-targeted phage in vivo.
To chase the fate of unmodified bacteriophage and phage with high affinity for an internalizing receptor, we metabolically labeled bacteriophage M13 with [
35 S]methionine/cysteine. The 35 S-radiolabeling enabled us to quantify phage particle recovery from tissue in an accessible, quick, and reproducible manner, with the advantage that also noninfectious phage can be assessed. This method will be particularly useful for the in vivo determination of internalizing phage. In contrast, 125 Iradiolabeling of phage leads to nonspecific liver uptake of nonviable phage (T. J. M. Molenaar et al., unpublished results; Johns et al., 2000) . Using 35 S-radiolabeled phage, we show that bacteriophage M13 is slowly cleared from the circulation with a half-life of 4.5 h in C57Bl/6 mice (around 4 h in 129/ICR white mice). Uptake was mainly by spleen and liver, pointing at uptake by the reticuloendothelial system (RES). The RES is mainly active in liver, spleen, and lungs and contains a well-defined lysosomal system that is specifically equipped to take up, kill, and degrade invading microorganisms. Recovery of virulent phage in organs such as lungs, liver, and spleen was considerably lower (4-5ϫ) than that of 35 S-radioactivity already at 30 min after injection, pointing at substantial disintegration of phages in these organs after uptake and processing by the RES. In kidney and heart, inactivation of M13 was not visible, suggesting that uptake in these organs is by a nondegrading system or that the phage recovered from heart and kidney are merely trapped in capillaries. This is the first time that a clear biodistribution profile of bacteriophage M13 is presented in mice. That seems surprising, because the use of M13 in vivo and in vitro has tremendously increased over the last couple of years, not only as a result of the many peptide and antibody phage display selections, but also due to recent advances in immunization experiments with phage-displayed peptides (Bastien et al., 1997; Frenkel et al., 2000; Galfre et al., 1996; Grabowska et al., 2000; Meola et al., 1995; Yu et al., 2000) and gene therapy using (recombinant) bacteriophage M13 (Larocca et al., 1998 Giovine et al., 2001) . For example, knowledge on the fate of wild-type M13 may be used to optimize the efficiency of immunization studies.
To investigate the in vivo fate of receptor-targeted phage, we chemically modified M13 by conjugation of a specific ligand to the protein coating of M13. Several chemical modifications to proteins have been described to confer receptor-specific uptake of proteins. Lactosylated low-density lipoprotein (LDL) is taken up by parenchymal cells and Kupffer cells in the rat liver (Bijsterbosch and Van Berkel, 1990 ). In addition, anionic ligands such as acetylated LDL or succinylated HSA are known as specific ligands for scavenger receptors on macrophages and sinusoidal liver cells (Nagelkerke et al., 1983; Kamps et al., 1997; Jansen et al., 1993b) . Both succinylation and lactosylation modify lysine residues. Succinylation of M13 will lead to the introduction of negative charges on the phage surface instead of the positively charged lysines; lactosylation does not alter the surface charge as the lysine can still be protonated (Schwartz and Gray, 1977) . Analogously, it is anticipated that succinylated bacteriophage M13 will target scavenger receptors on macrophages in liver and spleen, while lactosylated M13 would enable us to investigate the possible extravasation of M13 to subendothelial parenchymal cells. Indeed, lactosylated (lacM13) or succinylated bacteriophage M13 (sucM13) display a completely altered biodistribution profile than M13. LacM13 and sucM13 are cleared from the circulation with half-lives of 18 and 1.5 min, respectively, reflecting the high affinity of the ligands for the targeted receptors. Lactosylated M13 is taken up exclusively by the liver at 30 min after injection, while succinylated M13 can be recovered from both liver and spleen. Apparently, scavenger receptors and the galactose particle receptor are capable of rapid internalization of these large particles.
An important limitation to the phage display selections in vivo is the fact that selections can only be accomplished for endothelial targets, as extravasation of phage was suggested to be slow (Yip et al., 1999; Pasqualini and Ruoslahti, 1996) . In particular, phage which are readily internalized in vitro might not be able to reach their target in vivo at all. This is confirmed by the lacM13 biodistribution experiment. Although the size limit for the ASGPr for spheric particles is 70 nm (Rensen et al., unpublished observations) , the uptake of nonspheric lacM13 by isolated parenchymal cells in vitro is rapid and lactose specific. However, the parenchymal cells appear to be quite inaccessible in vivo. The large size of the phage (6 ϫ 500 nm) suggests that phage are unlikely to pass the fenestrae (ϳ100 nm in diameter) (Wisse et al., 1985) and that hepatic uptake can be mainly attributed to the galactose particle receptor on Kupffer cells. Nevertheless, 8% of the lactosylated M13 are still able to reach the PCs, possibly due to their flexible, rod-like geometry. These results confirm that extravasation of infectious phage to subendothelial tissue does occur, albeit at a slow rate. Therefore, when selecting for subendothelial targets, the first rounds of selection (having only a few copies per individual phage clone) should be accomplished in vitro, to enhance the copy number of the phage, a strategy employed by Samoylova and Smith to isolate muscle binding peptides (Samoylova and Smith, 1999) .
A second hurdle which might be encountered in in vivo biopanning is the loss of infectivity due to lysosomal degradation after uptake. The infectivity of lactosylated M13, succinylated M13, and unmodified M13 in the internalizing organs was reduced by 45-73% within the first 30 min after injection. For sucM13, phage internalization proceeds very rapidly: within 20 min after injection, Ͼ95% of the liver-associated sucM13 is inaccessible to sucHSA competition. Interestingly, degradation of sucM13 is only observed after a minimal lag time of 10 min (liver, spleen, lungs) or 30 min (kidney, heart). This lag time probably reflects intracellular transport of the phage to subcellular compartments and subsequent degradation. Uptake by scavenger receptors proceeds via a lysosomal route, and the processing of internalized macromolecules is very fast (10 min), especially in the liver macrophages. These kinetic studies on phage internalization in vivo imply that for in vivo phage selection, the circulation time must generally not exceed 10 min. Due to premature degradation of internalized phage, the first round of selection is particularly critical, because often Ͻ100 copies are present per individual phage clone. The rapid degradation of internalized phage also stresses the importance of radiolabeling for quantitative assessment of selected phage as CFU values will provide considerable underestimation of real uptake.
A third implication of this study is that phage can be redirected to specific cell types in vivo by chemical modification with high-affinity ligands for cell-specific receptors. It has already been shown in vitro that gene transfer can be established by using chemically (Larocca et al., 1998) or genetically Giovine et al., 2001 ) targeted phage. Peptides isolated via phage display have been used to retarget adenovirus gene delivery to airway epithelial cells (Romanczuk et al., 1999) and endothelial cells (Nicklin et al., 2000) . Chemical modification of M13 phage did not affect the integrity and infectivity of the phage, while considerably altering its biodistribution profile and its ability to enter specific cell types. In this respect, chemical modification may be an accessible strategy to improve efficacy and specificity of phage. A major advantage of bacteriophage M13 in gene delivery strategies as compared to adenoviral vectors might be its very low nonspecific uptake. However, the slow extravasation of phage into the subendothelial tissue suggests that the use of bacteriophage as gene delivery vectors might be restricted to the endothelium. Apart from gene delivery using recombinant phage, the retargeting of M13 might also be used for other purposes. Immunization of organisms using phage-displayed peptides (Bastien et al., 1997; Frenkel et al., 2000; Galfre et al., 1996; Grabowska et al., 2000; Meola et al., 1995; Yu et al., 2000) requires the uptake of M13 by antigen-presenting cells, including macrophages and dendritic cells. Succinylation of phage induces macrophage uptake, mainly through SR-A, and may thus be beneficial for antigen presentation by macrophages. Dendritic cells express scavenger receptors such as CD36 and CD68 (Matasic et al., 1999) . CD36 has a similar binding pattern as SR-A and is able to internalize polyanionic particles (Yamada et al., 1998; Terpstra et al., 2000) , and dendritic cells are therefore expected to take up succinylated, polyanionic, phage. We anticipate that the induced uptake of recombinant succinylated phage by macrophages and, probably, dendritic cells, leads to an improved immunization of phage displayed peptides or antibodies.
In conclusion, we show that 35 S-radiolabeled phage enables a more accurate quantification of the biodistribution profile and pharmacokinetics of wild-type and selected phage than by using infectivity assays, that targeted phage are rapidly internalized and degraded in vivo within 30-90 min after injection, and that extravasation of phage does occur, albeit at a very low rate. This has important implications for future in vivo selection protocols, for assessing the effectiveness of in vitro or in vivo selected phage, and for the potential use of phage as a viral gene-transfer vehicle.
MATERIALS AND METHODS
Materials
The phagemid pComb8 library, containing a CX 15 C insert, was a generous gift from H. Pannekoek, Amsterdam Medical Center, University of Amsterdam, The Netherlands. Succinic anhydride was from Janssen Chimica, Geel, Belgium. MOPS was from Boehringer Mannheim, Mannheim, Germany. Thiamine and BSA (fraction V) were obtained from Sigma, St. Louis, MO. D-Lactose and PMSF were supplied by Merck, Darmstadt, Germany. Sodium cyanoborohydride was from Aldrich, Brussels, Belgium. VCSM13 was from Stratagene, La Jolla, CA. Solvable was obtained from Packard, Meriden, USA. The SMART system, Sephacryl S1000 column, and the [ 35 S]methionine/cysteine promix were from AmershamPharmacia Biotech, Little Chalfort, U.K. The Mini Bead Beater was obtained from Biospec, Bartlesville, USA.
Mice
Wild-type C57Bl/6KH mice and 129/ICR white mice were obtained from Jackson Laboratories (Bar Harbor, ME) and bred in our local facility under specific pathogen-free conditions. All experiments were approved by the medical ethical committee on animal experiments of the Leiden University.
Determination of colony forming units
FЈ Escherichia coli (XL1-blue) was grown at 37°C to mid-log-phase in super broth media (30 g/l tryptone, 20 g/l yeast, 10 g/l MOPS), OD 600 ϭ 0.5-0.8. M13 bacteriophage library pComb8, containing an ampicillin-resistance gene, was diluted in phosphate-buffered saline (PBS) to an estimated amount of 100 infectious phage particles per 10 l PBS and allowed to infect 100 l of XL1-blue (10Ј, 37°C). Infected bacteria were plated on ampicillin-containing agar plates, incubated o/n at 37°C, and colonies (CFUs) were counted the next day.
Radiolabeling of bacteriophage M13
XL1-blue bacteria were infected with M13 and grown to OD 600 Ϸ 0.2. After infection of the bacteria with helper phage VCSM13 for 30 min, the bacteria were centrifuged and dissolved in M9 minimal medium (Sambrook et al., 1989) supplemented with ampicillin (10 g/ml), kanamycin (50 g/ml), thiamine (1 g/ml), and [
35 S]methionine/ cysteine promix (10 Ci/ml). Cultures were grown overnight at 37°C with shaking. Bacteria were pelleted by centrifugation and the metabolically labeled phage were precipitated from the supernatant by the addition of 1/5 vol 20% PEG6000/2.5 M NaCl and dissolved in PBS containing 0.2% sodium azide. Free 35 S was removed by repetitive precipitation of the phage until the pellet contained Ͼ97% of total radioactivity. The specific activity of 35 S-M13 phage was 10 Ϫ6 -10 Ϫ5 dpm/CFU.
Succinylation and lactosylation of M13
Succinylated-M13 (sucM13) was prepared by adding 2 l succinic anhydride (50 mg/ml in DMSO) to 100 l M13 (10 12 CFU in 0.2 M K 2 HPO 4 , pH 8.0) and gently stirring the solution for 1 h at 4°C. Studies on succinylated human serum albumin, bovine serum albumin (BSA), and lowdensity lipoprotein have shown 60-100% succinylation of lysine residues after 1 h incubation (Jansen et al., 1993b; Swart et al., 1999; Haberland et al., 1984) .
To prepare lactosylated M13 (lacM13), bacteriophage M13 (10 10 CFU/l in 20 mM sodium phosphate buffer, pH 7.0) was incubated at room temperature with lactose and sodium cyanoborohydride to final concentrations of 100 and 50 mg/ml, respectively. After 5 h, the reaction was quenched by adding 10 vol 0.1 M glycine and dialyzed exhaustively against PBS. The degree of lactosylation of M13 was determined using [
14 C]lactose. After 5 h, approximately 25% of the maximal binding by lysine residues (1 pmol/g protein) was observed (not shown). The recoveries of phage titers (CFU) after succinylation and lactosylation of the phage varied between 80 and 100%.
Gel filtration analysis of sucM13 and lacM13 M13, lacM13, or sucM13 (10 9 CFU in 50 l PBS) was injected onto a SMART system, using a Sephacryl S-1000 SF column equipped with a 50-l sample loop, and eluted at a flow rate of 50 l/min with PBS (pH 7.4). Fractions (50 l) were collected and assayed for both 35 S-radioactivity and CFU.
In vivo serum clearance and tissue distribution
For short time-span studies (Ͻ30 min), mice (male, 25-30 g) were anesthetized, the abdomen opened, and 35 S-labeled M13 samples were injected in the vena cava inferior. For long-time spanning studies (1.5 and 6 h), injection was performed via the tail vein. At the indicated time points, blood samples were taken and allowed to clot for 30 min. The serum, obtained after centrifugation for 1 min at 16,000 g, was assayed for 35 S-radioactivity and CFUs. The half-lives of the injected phage were calculated with GraphPad Prism 3.0 (ISIS Software, Motulsky). After the last time point, mice were perfused with DMEM (RT, 100 mmHg) for 2 min at 10 ml/min via a cannula in the left ventricle of the heart, and organs were removed, weighed, and snap-frozen in liquid nitrogen. Organs were homogenized in 1 ml 0.1 M HCl pH 2.2 with 1 mm glass beads using a Mini Bead Beater and the amount of CFU in the organ was determined by infecting E. coli with diluted organ homogenate. The remaining fraction was dissolved in Solvable and assayed for 35 Sradioactivity.
Contribution of liver cell types to hepatic uptake
Mice were anesthetized and injected with 35 S-labeled lacM13 as described in the previous section. At 20 min after injection, the abdomen was opened, the vena cava was cannulated via the right ventricle of the heart, and the liver was perfused with Ca 2ϩ free Hank's balanced salt solution containing 10 mM HEPES, pH 7.4 at 14 ml/min. After 10 min a liver lobule was tied off for determination of the total liver uptake. The liver was subsequently perfused with 0.05% (w/v) collagenase in Hank's medium containing 10 mM HEPES, pH 7.4, and parenchymal cells and nonparenchymal cells were isolated as described previously (van Berkel et al., 1985) . Purity of the cells was assessed by phase-contrast microscopy, PCs being much larger than NPCs. Purity was Ͼ95%, contamination of NPC in PC fraction was Ͻ1%.
PC and NPC fractions were assayed for 35 S and CFUs. The contribution of the various cell types to the total liver uptake was calculated as described previously (Nagelkerke et al., 1983) . Protein concentrations of the PC and NPC fraction were determined by the method of Lowry et al. (1951) , with bovine serum albumine as standard.
In vitro uptake of lacM13 to parenchymal liver cells
Primary mouse parenchymal cells were isolated essentially as described above. Cells were washed twice with DMEM/2% BSA and the viability (Ͼ80%) was checked with 1.4 mg/ml trypan blue. Cells (Ϯ10 6 cells/ml) were incubated with lacM13 (10 11 CFU/ml) at 37°C under a carbogen atmosphere with constant agitation (150 rpm). Incubations with nonlactosylated phage at 37°C and incubations with lactosylated phage at 4°C were used as negative controls. After 2 h, cells were washed with ice-cold DMEM and incubated with DMEM/proteinase K (2 mg/ml) for 1 h to remove extracellular phage. Proteinase K was inactivated by the addition of 1 M PMSF at 4°C and cells were lysed by freeze thawing. Samples were assayed for CFUs.
